Number crunching: the search for potential therapies

R&D in the pharmaceutical industry is having a tough time. As blockbuster drugs fall foul of the so-called ‘patent cliff ’, and the cost of healthcare continues to rise, many big pharma companies, including Merck, Novartis and AstraZeneca, have resorted to laying off R&D staff to cut costs.